Víctor Cervera-Carrascón

1.1k citations

40 papers · 761 indexed · h-index 18

Co-authors: Akseli Hemminki Riikka Havunen João M. Santos Anna Kanerva Mikko Siurala Suvi Sorsa Dafne C.A. Quixabeira Sadia Zafar
Topics: Virus-based gene therapy research (36 papers)CAR-T cell therapy research (35 papers)Immunotherapy and Immune Responses (14 papers)
Cited by: Oncology Biotechnology Genetics
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaAnnals of Oncology
Partner nations: Finland Netherlands Denmark

In The Last Decade

Víctor Cervera-Carrascón

40 papers receiving 753 citations

Peers

Countries citing papers authored by Víctor Cervera-Carrascón

Since Specialization

Citations

This map shows the geographic impact of Víctor Cervera-Carrascón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Víctor Cervera-Carrascón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Víctor Cervera-Carrascón more than expected).

Fields of papers citing papers by Víctor Cervera-Carrascón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Víctor Cervera-Carrascón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Víctor Cervera-Carrascón. The network helps show where Víctor Cervera-Carrascón may publish in the future.

Co-authorship network of co-authors of Víctor Cervera-Carrascón

This figure shows the co-authorship network connecting the top 25 collaborators of Víctor Cervera-Carrascón. A scholar is included among the top collaborators of Víctor Cervera-Carrascón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Víctor Cervera-Carrascón. Víctor Cervera-Carrascón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Katriina Peltola,Tuomo Alanko,(unknown),Teijo Pellinen,(unknown),Dafne C.A. Quixabeira,(unknown),Riikka Havunen,Suvi Sorsa,João M. Santos,Víctor Cervera-Carrascón,Akseli Hemminki	2
2	Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models 2025 ·Cancer Immunology Immunotherapy ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Susanna Grönberg-Vähä-Koskela,Dafne C.A. Quixabeira,João M. Santos,Víctor Cervera-Carrascón,Otto Hemminki,Anna Kanerva,Harri Mustonen,Pauli Puolakkainen,Hanna Seppänen,Akseli Hemminki	1
3	Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma 2025 ·PubMed ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Dafne C.A. Quixabeira,(unknown),(unknown),Susanna Grönberg-Vähä-Koskela,Anna Kanerva,Antti Rannikko,João M. Santos,Víctor Cervera-Carrascón,Otto Hemminki,Akseli Hemminki	2
4	Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma 2024 ·Immuno-Oncology Technology ·(unknown),(unknown),(unknown),(unknown),Eva Ellebæk,Marco Donia,Rikke Løvendahl Eefsen,Christian von Buchwald,Claudia Kistler,João M. Santos,(unknown),(unknown),Marie Christine Wulff Westergaard,Dafne C.A. Quixabeira,(unknown),Riikka Havunen,(unknown),Víctor Cervera-Carrascón,(unknown),Inge Marie Svane	2
5	Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine 2023 ·Cancer Gene Therapy ·Dafne C.A. Quixabeira,(unknown),(unknown),Riikka Havunen,(unknown),João M. Santos,(unknown),(unknown),(unknown),(unknown),Susanna Grönberg-Vähä-Koskela,Víctor Cervera-Carrascón,Annukka Pasanen,Marjukka Anttila,Johanna Tapper,Anna Kanerva,Akseli Hemminki	7
6	An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage 2023 ·Frontiers in Immunology ·(unknown),Dafne C.A. Quixabeira,(unknown),(unknown),Susanna Grönberg-Vähä-Koskela,(unknown),(unknown),(unknown),(unknown),Camilla Heiniö,João M. Santos,Víctor Cervera-Carrascón,Riikka Havunen,Marjukka Anttila,Akseli Hemminki	4
7	48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial 2023 ·Immuno-Oncology Technology ·(unknown),(unknown),Brigitte Dréno,Víctor Cervera-Carrascón,Eva Ellebæk,Marco Donia,Amir Khammari,Claudia Kistler,(unknown),(unknown),(unknown),(unknown),(unknown),Dafne C.A. Quixabeira,(unknown),Riikka Havunen,(unknown),Suvi Sorsa,Akseli Hemminki,Inge Marie Svane	1
8	1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO) 2023 ·SHILAP Revista de lepidopterología ·João M. Santos,Katriina Peltola,Tuomo Alanko,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Juha Kononen,(unknown),Claudia Kistler,Suvi Sorsa,Riikka Havunen,Víctor Cervera-Carrascón,Akseli Hemminki	2
9	Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors 2022 ·Molecular Therapy — Oncolytics ·(unknown),João M. Santos,Dafne C.A. Quixabeira,(unknown),Susanna Grönberg-Vähä-Koskela,(unknown),(unknown),(unknown),Camilla Heiniö,Riikka Havunen,Víctor Cervera-Carrascón,Suvi Sorsa,Marjukka Anttila,Anna Kanerva,Akseli Hemminki	8
10	Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer 2022 ·Frontiers in Immunology ·(unknown),(unknown),Camilla Heiniö,(unknown),(unknown),Víctor Cervera-Carrascón,João M. Santos,Dafne C.A. Quixabeira,Riikka Havunen,Suvi Sorsa,(unknown),Tuula Salo,Leif Bäck,Katri Aro,(unknown),(unknown),Akseli Hemminki	32
11	Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control 2021 ·Frontiers in Immunology ·Dafne C.A. Quixabeira,Sadia Zafar,João M. Santos,Víctor Cervera-Carrascón,Riikka Havunen,(unknown),(unknown),Marjukka Anttila,Anna Kanerva,Akseli Hemminki	28
12	1032TiP A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes 2021 ·Annals of Oncology ·Inge Marie Svane,João M. Santos,Víctor Cervera-Carrascón,Riikka Havunen,Suvi Sorsa,Eva Ellebæk,(unknown),Marco Donia,Amir Khammari,Brigitte Dréno,Akseli Hemminki	4
13	Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples 2020 ·Human Gene Therapy ·Sadia Zafar,(unknown),(unknown),Dafne C.A. Quixabeira,João M. Santos,Otto Hemminki,(unknown),Víctor Cervera-Carrascón,Pasi Aronen,(unknown),Riikka Havunen,Antti Rannikko,Tuomas Mirtti,Mika Matikainen,Anna Kanerva,Akseli Hemminki	21
14	Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes 2020 ·Cancer Gene Therapy ·Sadia Zafar,Dafne C.A. Quixabeira,(unknown),Víctor Cervera-Carrascón,João M. Santos,Susanna Grönberg-Vähä-Koskela,Fang Zhao,Pasi Aronen,Camilla Heiniö,Riikka Havunen,Suvi Sorsa,Anna Kanerva,Akseli Hemminki	15
15	Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors 2020 ·Molecular Therapy — Oncolytics ·Víctor Cervera-Carrascón,Dafne C.A. Quixabeira,Riikka Havunen,João M. Santos,(unknown),(unknown),Mikko Siurala,Camilla Heiniö,Sadia Zafar,Teija Koivula,(unknown),(unknown),J. Arturo García‐Horsman,Anu J. Airaksinen,Suvi Sorsa,Marjukka Anttila,Veijo Hukkanen,Anna Kanerva,Akseli Hemminki	35
16	Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. 2019 ·Expert Opinion on Biological Therapy ·Víctor Cervera-Carrascón,Riikka Havunen,Akseli Hemminki	27
17	TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade 2018 ·OncoImmunology ·Víctor Cervera-Carrascón,Mikko Siurala,João M. Santos,Riikka Havunen,Siri Tähtinen,(unknown),Suvi Sorsa,Anna Kanerva,Akseli Hemminki	90
18	Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus 2018 ·Molecular Therapy — Oncolytics ·Riikka Havunen,João M. Santos,Suvi Sorsa,Tommi Rantapero,(unknown),Mikko Siurala,Anu J. Airaksinen,Víctor Cervera-Carrascón,Siri Tähtinen,Anna Kanerva,Akseli Hemminki	45
19	Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy 2018 ·Molecular Therapy ·João M. Santos,Víctor Cervera-Carrascón,Riikka Havunen,Sadia Zafar,Mikko Siurala,Suvi Sorsa,Marjukka Anttila,Anna Kanerva,Akseli Hemminki	44
20	Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma 2016 ·Molecular Therapy ·Mikko Siurala,Riikka Havunen,Dipongkor Saha,(unknown),Anu J. Airaksinen,Siri Tähtinen,Víctor Cervera-Carrascón,Simona Bramante,Suvi Parviainen,Markus Vähä‐Koskela,Anna Kanerva,Akseli Hemminki	43

About Víctor Cervera-Carrascón

Víctor Cervera-Carrascón is a scholar working on Biotechnology, Oncology and Genetics, having authored 40 papers that have together received 761 indexed citations. Recurring topics across this work include Virus-based gene therapy research (36 papers), CAR-T cell therapy research (35 papers) and Immunotherapy and Immune Responses (14 papers). The work is most often cited by research in Oncology (597 citations), Biotechnology (167 citations) and Genetics (513 citations). Víctor Cervera-Carrascón has collaborated with scholars based in Finland, Netherlands and Denmark. Frequent co-authors include Akseli Hemminki, Riikka Havunen, João M. Santos, Anna Kanerva, Mikko Siurala, Suvi Sorsa, Dafne C.A. Quixabeira, Sadia Zafar, Camilla Heiniö and Siri Tähtinen. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact